Similar articles

• B-cell depletion and repopulation in autoimmune diseases.

  Pers JO, Daridon C, Bendaoud B, Devauchelle V, Berthou C, Saraux A, Youinou P. Pers JO, et al. Clin Rev Allergy Immunol. 2008 Feb;34(1):50-5. doi: 10.1007/s12016-007-8015-4. Clin Rev Allergy Immunol. 2008. PMID: 18270858 Review.
• Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.

  Pollard RP, Abdulahad WH, Bootsma H, Meiners PM, Spijkervet FK, Huitema MG, Burgerhof JG, Vissink A, Kroese FG. Pollard RP, et al. Ann Rheum Dis. 2013 Dec;72(12):2048-50. doi: 10.1136/annrheumdis-2013-203447. Epub 2013 Jul 17. Ann Rheum Dis. 2013. PMID: 23864239 Clinical Trial. No abstract available.
• [Is rituximab a promising treatment for Sjögren's syndrome?].

  Devauchelle-Pensec V, Pers JO, Youinou P, Saraux A. Devauchelle-Pensec V, et al. Rev Med Interne. 2008 Dec;29(12):967-70. doi: 10.1016/j.revmed.2008.02.022. Epub 2008 Apr 9. Rev Med Interne. 2008. PMID: 18403066 French. No abstract available.
• Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.

  Hamza N, Bootsma H, Yuvaraj S, Spijkervet FK, Haacke EA, Pollard RP, Visser A, Vissink A, Kallenberg CG, Kroese FG, Bos NA. Hamza N, et al. Ann Rheum Dis. 2012 Nov;71(11):1881-7. doi: 10.1136/annrheumdis-2011-201189. Epub 2012 May 21. Ann Rheum Dis. 2012. PMID: 22615459
• Anti-CD20 antibody in primary Sjögren's syndrome management.

  Chen S, Liu Y, Shi G. Chen S, et al. Curr Pharm Biotechnol. 2014;15(6):535-41. doi: 10.2174/138920101506140910150431. Curr Pharm Biotechnol. 2014. PMID: 25213362 Review.